Old and new antithrombotic drugs in neonates and infants

Seminars in Fetal and Neonatal Medicine

Volumn 16, Issue 6, 2011, Pages 349-354

  Young, Guy ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anticoagulaton; Neonates; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; REVIPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; INFANT; INFANT, NEWBORN; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; POLYSACCHARIDES; RECOMBINANT PROTEINS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 80053605037     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2011.07.002     Document Type: Review

References (49)

1. Yank J.Y.K., Chan A.K.C. Neonatal systemic venous thrombosis. Thromb Res 2010, 126:471-476.
2. Raffini L., Huang Y., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001-2007. Pediatrics 2009, 124:1001-1008.
3. Monagle P., Chalmers E., Chan A., deVeber G., Kirkham F., Massicotte P., Michleson A.D. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008, 133:887-968. 8th ed.
4. Kakzanov V., Monagle P., Chan A.K. Thromboembolism in infants and children with gastrointestinal failure receiving long-term parenteral nutrition. J Parenter Enteral Nutr 2008, 32:88-93.
5. Kuhle S., Massicotte P., Chan A., Mitchell L. A case series of 72 infants with renal vein thrombosis. Data from the 1-800-NO-CLOTS registry. Thromb Haemost 2004, 92:729-733.
6. Sutor A.H., Massicotte P., Leaker M., Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost 1997, 23:303-319.
7. Newall F., Johnston L., Ignatovic V., Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics 2009, 123:e510-e518.
8. Newall F., Ignatovic V., Johnston L., et al. Clinical use of unfractionated heparin therapy in children: time for a change?. Br J Haematol 2010, 150:674-678.
9. Kitchen S., Theaker J., Preston F.E. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coag Fibrin 2000, 11:137-144.
10. Severin T., Sutor A.H. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001, 27:293-299.
11. Kishimoto T.K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008, 358:2457-2467.
12. Hirsh J., Levine M.N. Low molecular weight heparin. Blood 1992, 79:1-17.
13. Samama M.M., Gerotziafas G.T. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000, 26(Suppl.):131-138.
14. Massicotte P., Julian J.A., Marzinotto V., et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003, 109:93-99.
15. Massicotte P., Adams M., Marzinotto V., Brooker L.A., Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996, 128:313-318.
16. Punzalan R.C., Hillery C.A., Montgomery R.R., Scott C.A., Gill J.C. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000, 22:137-142.
17. Albisetti M., Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002, 161:71-77.
18. O'Brien S.H., Lee H., Ritchey A.K. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. J Thromb Haemost 2007, 5:1985-1987.
19. Rajgopal R., Bear M.K., Shaugnessy S.G. The effects of heparin and low molecular weight heparin on bone. Thromb Res 2008, 122:293-298.
20. Massicotte M.P. Low-molecular-weight heparin therapy in children. J Pediatr Hematol Oncol 2000, 22:98-99.
21. Nohe N., Flemmer A., Rumler R., Praun M., Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999, 158(Suppl. 3):S134-S139.
22. Kuhle S., Massicotte P., Dinyari M., et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005, 94:1164-1171.
23. Andrew M., Marzinotto V., Brooker L.A., et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994, 71:265-269.
24. Streif W., Andrew M., Marzinotto V., et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999, 94:3007-3014.
25. Woods A., Vargas J., Berri G., Kreutzer G., Meschengieser S., Lazzari M.A. Antithrombotic therapy in children and adolescents. Thromb Res 1986, 42:289-301.
26. Gunther T., Mazzitelli D., Schreiber C., et al. Mitral-valve replacement in children under 6 years of age. Eur J Cardiothorac Surg 2000, 17:426-430.
27. Wermes C., Bergmann F., Reller B., Sykora K.W. Severe protein C deficiency and aseptic osteonecrosis of the hip joint: a case report. Eur J Pediatr 1999, 158(Suppl. 3):S159-S161.
28. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991, 324:1865-1875.
29. Young G. New anticoagulants in children. Hematol Am Soc Educ Program 2008, 1:245-250.
30. Chan V.H.T., Monagle P., Massicotte P., Chan A.K.C. Novel paediatric anticoagulants: a review of the current literature. Blood Coag Fibrin 2010, 21:144-151.
31. Deitcher S.R., Topoulos A.P., Bartholomew J.R., Kichuk-Chrisant M.R. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr 2002, 140:264-266.
32. Cetta F., Graham L.C., Wrona L.L., Arruda M.J., Walenga J.M. Argatroban use during pediatric interventional cardiac catheterization. Catheter Cardiovasc Interv 2004, 61:147-149.
33. Kawada T., Kitagawa H., Hoson M., Okada Y., Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000, 14:445-457.
34. Severin T., Zieger B., Sutor A.H. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost 2002, 28:447-454.
35. Young G., Tarantino M.D., Wohrley J., Weber L.C., Belvedere M., Nugent D.J. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007, 5:1654-1659.
36. Rayapudi S., Torres A., Deshpande G.G., et al. Bivalirudin for anticoagulation in children. Pediatr Blood Cancer 2008, 51:798-801.
37. Forbes T.J., Hijazi Z., Young G. Bivalirudin as a procedural anticoagulant in the pediatric population undergoing intravascular procedures for congenital heart disease. Catheter Cardiovasc Interv 2011, 77:671-679.
38. Young G., Boshkov L.K., Sullivan J.E., et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer 2011, 56:1103-1109.
39. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163:1849-1856.
40. Madabushi R., Cox D.S., Hossain M., et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharm 2011, 51:19-28.
41. Gross P.L., Weitz J.I. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008, 28:380-386.
42. Young G., Nugent D.J. Use of argatroban and fondaparinux in a child with heparin-induced thrombocytopenia. Pediatr Blood Cancer 2004, 42(Suppl.):542. (abstract).
43. Boshkov L.K., Kirby A., Shen I., et al. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. Ann Thorac Surg 2006, 81:S2355-S2359.
44. Grabowski E.F., Bussell J.B. Pediatric experience with fondaparinux in deep vein thrombosis. Blood 2006, 108:916. (abstract).
45. Sharatkumar A.A., Crandall C., Lin J.J., et al. Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy. J Pediatr Hematol Oncol 2007, 29:581-584.
46. Young G, Yee DL, O'Brien S, Khanna R, Nugent DJ. FondaKIDS: a prospective dose-finding, pharmacokinetic, and safety study of fondaparinux in children between 1-18 years of age.
47. Garcia D., Libby E., Crowther M.A. The new oral anticoagulants. Blood 2010, 115:15-20.
48. Almond C.S., Harrington J., Thiagarajan R., et al. Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J Heart Lung Transplant 2006, 25:1376-1379.
49. Lobo B., Finch C., Howard A., Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008, 99:208-214.